Our Development Pipeline

We are strategically building a development pipeline in rare dermatologic diseases that have no approved treatments. All of our development programs qualify for Orphan Drug status. In addition, all of our investigational products have significant market expansion potential into major medical dermatology indications including acne, port wine stains and tissue scarring. Clinical proof of concept has already been established in two of our late-stage clinical development programs.

TMB-001

TMB-001 (topical isotretinoin) is being developed for the treatment of moderate to severe subtypes of CI.

TMB-002

TMB-002 (topical rapamycin) is being developed for the treatment of FAs in TSC.

TMB-003

TMB-003 (topical / subcutaneous ET-A receptor antagonist) is under preclinical evaluation for Localized Scleroderma.

If you are interested in any of Timber’s ongoing clinical research programs, please contact trials@timberpharma.com.